BioNTech WKN: A2PSR2 ISIN: US09075V1026 Kürzel: BNTX Forum: Aktien Thema: Hauptdiskussion

Tobse in welchem Forum?

Ich zutier Resticco aus dem Gedächgnis: „der Kurs dieser S. Aktie wird fallen. Auf mindestens 45“ „ich gönne es euch allen ihr...“ Ganz im ernst, der typ ist wirklich ganz unterste sorte, hatte ihn dann ignoriert- empfehle ich euch auch..

Also wenn der Kurs hoch schießt geht er auch wieder ordentlich runter (Gewinnmitnahmen), nur wer dann ruhig bleibt erntet am Ende deutlich mehr.

Tageshoch🥳

Ich hoffe, er steigt bis 15:30 nicht zu steil, sonst „put the American a damper on“.....

Meine Info habt ihr gelesen?

😉

Wenn Resticco Long ist gehe ich besser mal Short

An ein mögliches Scheitern glaube ich nicht mehr.

Könnte sein das wir schon heute den Höchstand erreichen?

@magisch Ich bin long und der Kurs steigt, läuft.

Für unser amerikanischen Freunde die hier mitlesen: The Mainz-based company Biontech reports a breakthrough: the newly developed Corona vaccine works very well. Now mass vaccinations could soon take place. Researcher couple Sahin/Türeci would not only achieve billions of dollars, but also world fame. The world is waiting for a Corona vaccine. Redemption could now come from Rheinhessen. The Mainz-based pharmaceutical company Biontech reports that the newly developed vaccine BNT162b2 is so successful in clinical trials that on the one hand mass production has begun and on the other hand the final approval process has been requested. He said, "We're about to put an end to this pandemic#34.#34; Biontech Biontech 77.08 The European Pharmaceutical Authority (EMA) in Amsterdam confirms that the active substance is now being tested in the so-called "Rolling Review process" In this procedure, data from the clinical trial are submitted and evaluated on an ongoing basis. According to the Authority, the EMA's decision to start this rapid procedure is based on the encouraging data from clinical trials in adults vaccinated so far. In April, Biontech became the first German company to receive approval for clinical trials from the Paul Ehrlich Institute. In the meantime, the Mainzers have already included 37,000 participants in the studies, 28,000 people have already received the second dose of the vaccine, it was said. More than 120 study centers worldwide are involved, including in the United States, Brazil, South Africa and Argentina. Ugur1.jpg Ugur Sahin (Photo: Biontech) As Biontech CEO and co-founder Ugur Sahin points out, "slowly towards the finish line". In an interview in the "Frankfurter Allgemeine Zeitung" he says that "with twenty candidates" started research, "four we have clinically tested". And BNT162b2 is "very promising". The vaccine has "an excellent profile" - and Sahin is convinced that "we have a safe product and are able to demonstrate effectiveness". Biontech is so enthusiastic about its vaccine that mass production has already begun, so delivery is just waiting for approval. Federal Health Minister Jens Spahn also suddenly expects that the first Corona vaccinations could take place this winter, as he said at a video conference of the Ifo Institute. Spahn pointed out, however, that several technologies and manufacturers are used. "When all the horses reach the finish line, we will have far too much vaccine". Production site purchased 9a11fba321e076746c9609ddfa430daf.jpg Economy 17.09.20 Production of Corona vaccine Biontech buys Novartis plant The fact that a vaccine is already available a few months after the outbreak of the pandemic is a scientific sensation. Normally, vaccine developments and approvals take several years. However, whether millions of doses of vaccine will actually be administered this year depends on the EMA's auditors and a quick approval. "In any case, we will present our data sets accordingly - and present transparent effects and side effects. Vaccine doses will also be in stock", Sahin said. In fact, Biontech in Marburg, Hesse, bought the production facility of the Swiss pharmaceutical company Novartis, together with 300 highly qualified employees, in order to be able to ramp up mass production quickly. So one of the largest Corona vaccine production sites in the world could soon be built there. Biontech is planning 100 million doses of vaccine this year, 250 million in the first half of 2021. In the next few years, production is expected to increase to 750 million doses of vaccine per year. For Marburg, this also means the comeback of a traditional pharmaceutical research location, because With Constantin Zwenger (1814-1884) pharmaceutical chemistry was founded here. Marburg, with Emil Adolf Behring (1864-1917), is the first Nobel laureate in medicine and the founder of passive vaccination. The University of Marburg is still a worldwide research leader in chemistry and biology, and numerous Leibniz prizes bear witness to this. Ozlem1.jpg Özlem Türeci (Photo: Biontech) If the Mainz-Marburg vaccine does indeed prevail, this would also be good news for many thousands of Biontech shareholders. The share price has already tripled since March. The market capitalisation of the young company has exceeded the 20 billion dollar mark - thus Biontech is worth three to four times as much as Lufthansa or Commerzbank. The medical couple Ugur Sahin and Özlem Türeci should also be pleased about this. Because the two are not only exceptionally successful researchers of medicine, now they are also billionaires. Biontech's two founders still hold 18 percent of the share capital. With the spectacular success of their company, they have suddenly risen among the 100 richest Germans. Pioneers of Cancer Research Germany, along with the couple, is given a shining example for successful integration. Sahin's family came to Cologne from Turkey when he was four years old. His father was a guest worker at Ford. Sahin first studied medicine in Cologne, later he worked as a doctor at the clinic of the University of Cologne. He wrote his doctoral thesis on immunotherapy in tumor cells. Since then, his focus has been on cancer research and immunology. Since 2006 Sahin has been Professor of Experimental Oncology at the University Of Mainz University Hospital. Dr. Specht Biontech.JPG Panorama 17.09.20 Biontech's Vaccine Update Dr. Specht: "Sounds very good" His wife Özlem Türeci also has Turkish roots: her father came to Germany as a doctor from Istanbul to work in a small Catholic hospital in the district of Cloppenburg. Türeci studied medicine in Saarland and met her husband at the cancer ward of the hospital in Homburg an der Saar. Both were fascinated by the idea of being able to treat cancer in a new way than just with surgery, chemotherapy and radiation. They wanted to get the immune system to attack the cancer cells themselves - and they succeeded. Together, they founded Ganymed Pharmaceuticals in 2001, which focused on antibody drugs against tumors. The company has since been able to sell them for a three-digit million sum. Sahin and Türeci are internationally regarded as pioneers of cancer immunotherapy. And now, because they quickly turned their research into a pandemic, they could become science heroes of the Corona fight. But their cancer patients don't lose sight of them. They also want to help them with the vaccine: "I hope that we will enable risk groups like our cancer patients, some of whom no longer dare to take to the streets, to reconnect with others"," says Sahin. Whether billions of dollars or billions of doses of vaccination. He points out: "Behind the big numbers are many individual individuals who can benefit from it."

LyonTrader, das währe ganz Böse.

So ihr Lieben, die NTV News wurde soeben im Ami Forum gepostet!

Bin bei 50 Euro rein plus 60 Prozent so geil und bei 70 all im nachgekauft ole ole i freu mich

Ich will gar nicbt dran denken, falls sie die Genehmigung nicbt bekommen sollten